Introduction
============

Prostate carcinoma is the most frequently diagnosed visceral cancer in men worldwide. An increasing prevalence has been reported in recent decades ([@b1-or-31-03-1067]). Radiation therapy is one of the primary modalities in prostate cancer treatment. Ionizing radiation damages cells through free radicals from the radiolysis of water that cause DNA double-strand breaks. However, the efficacy of the radiotherapy may be affected by the cellular response to radiation. Radiotherapy is highly effective in treating radiosensitive tumors and enhancing the therapeutic efficacy can increase the overall survival rate. However, the presence of radioresistant tumors leads to cancer relapse and metastasis. Understanding the tumor-radiation-related genes to predict the tumor response to radiotherapy may potentially modulate the treatment outcome for prostate cancer patients.

MicroRNAs (miRNAs) are a family of small, non-coding, single-stranded RNAs composed of \~22 nucleotides (nt) that negatively regulate protein expression at the post-transcriptional level ([@b2-or-31-03-1067]). They function as gene regulators by binding to partially complementary sites of mRNAs and cause translation inhibition or direct degradation of the target mRNA. It has been suggested that miRNAs are responsible for controlling \~50% of all protein-coding genes ([@b3-or-31-03-1067]). The widespread regulation of protein levels has been studied in cellular models ([@b4-or-31-03-1067]). Previous studies have demonstrated that the expression of miRNAs is clearly involved in cancer development, and the deregulation of several miRNAs has been observed in various types of cancer, including prostate cancer. Porkka *et al* ([@b5-or-31-03-1067]) was the first to identify a miRNA signature specific for prostate cancer by systematically profiling prostate cancer cell lines. Numerous studies have identified many dysfunctional miRNAs by using a high-throughput approach, which contributed to prostate cancer progression, including the let-7 family, miR-1, -20a, -21,-34a, -106b, -125b, -205 and -521 ([@b6-or-31-03-1067]--[@b13-or-31-03-1067]). Although several studies have investigated the role of these dysfunctional miRNAs to develop prostate cancer therapy, few studies have determined the roles of miRNAs in radiation response in prostate cancer. The upregulation of miR-521 reduces the response to radiation damage by specifically targeting a DNA repair protein, the Cockayne syndrome protein A ([@b13-or-31-03-1067]). Li *et al* ([@b14-or-31-03-1067]) found that miR-106b was dysregulated after radiation treatment and suppressed radiation-induced p21 activation, suggesting it may override radiation-induced cell cycle arrest and cell growth inhibition. Radiation delivered in daily fractions altered a greater number of miRNAs compared with single-dose radiation, and involved the upregulation of miR-34a and let-7 miRNAs ([@b15-or-31-03-1067]).

Next-generation sequencing (NGS) is a high-throughput screening technology, and NGS data can be applied in investigating miRNA expression, miRNA isoforms (isomiRs) and the arm selection preferences of miRNAs. Therefore, the purpose of the present study was to comprehensively investigate the distribution of miRNAs after radiation treatment in PC3 cells by using an NGS approach. Furthermore, we explored the function of radiation-associated miRNA by conducting an *in silico* analysis.

Materials and methods
=====================

Cell culture and radiation treatment
------------------------------------

A PC3 cell line was obtained from the American Type Culture Collection and was maintained in RPMI-1640 and supplemented with 10% inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA). The cells were exposed to various radiation dosages (0, 2, 6, 10, 14 and 18 Gy) and were subsequently cultured in fresh medium. The total RNA was obtained at various time points (0, 5, 15 and 40 h after treatment) by using TRIzol (Invitrogen) according to the manufacturer's instructions. The concentration, purity and amount of total RNA were determined using a NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Inc., USA).

Collection and preprocessing of sequence reads
----------------------------------------------

PC3 cells were exposed to 10 Gy of radiation. After radiation treatment, the cells were lysed at various time points (0, 5, 15 and 40 h) for RNA extraction. The RNA samples were prepared using an Illumina small RNA preparation kit, and were subsequently sequenced using the Illumina HiSeq platform. The generated sequence reads were first subjected to quality control to remove low-quality reads. The sequence reads were then subjected to 3′ adaptor trimming to generate clean reads, as previously described ([@b15-or-31-03-1067],[@b16-or-31-03-1067]). To attain a high confidence level, only the clean reads with a read count ≥2 and with a length ranging from 15 to 27 nt were included in further analyses.

Mapping clean reads to pre-miRNAs
---------------------------------

To investigate miRNA expression profiles in different libraries, we mapped the qualified clean reads back to human pre-miRNAs (miRBase 19). To eliminate ambiguous multiple hits during the mapping procedure, no mismatch was allowed. Previous studies reported that, when mapped back to pre-miRNAs, sequence reads usually carried mismatches preferentially located at their terminal 3′ ends ([@b17-or-31-03-1067]--[@b20-or-31-03-1067]). This mismatch was named the 3′ end modification. To determine whether the 3′ end modification patterns differed among libraries, as described in our previous studies ([@b21-or-31-03-1067]), we trimmed and collected the terminal 3′ end mismatches one by one. In addition, the remaining perfect match reads had to be at least 18 nt in length. As a result, we kept reads with no less than 18-nt perfect alignment and 3′ end modification patterns.

Classifying non-miRNA reads into different data sets
----------------------------------------------------

The sequence reads that may not be mapped back to pre-miRNAs were classified into classes by mapping to acquire different data sets with Bowtie ([@b22-or-31-03-1067]) and allowing a single nucleotide variation. The sequences of mRNAs and other ncRNAs were derived from the NCBI RefSeq 47 ([@b23-or-31-03-1067]). The tRNA sequences were downloaded from the Genomic tRNA database ([@b24-or-31-03-1067]) and the rRNA sequences were downloaded from the SILVA database ([@b25-or-31-03-1067]). The snoRNA, scaRNA and snRNA sequences were all downloaded from NONCODE ([@b26-or-31-03-1067]). The sequence reads not belonging to any of the described RNA classes were uploaded to the RepeatMasker to identify repeat elements, which were classified as unknown.

miRNA expression level according to The Cancer Genome Atlas (TCGA) data
-----------------------------------------------------------------------

TCGA project collects both cancer and corresponding normal tissues from hundreds of prostate cancer patients. We downloaded all level-3 miRNA expression data of prostate adenocarcinoma from the TCGA Data Portal (<https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm>). These level-3 data included calculated expressions for each miRNA derived from the Illumina HiSeq sequencing results. A total of 198 tumor samples and 50 normal samples were found at the time the data were downloaded. We kept only the expression data of 50 participants who had both miRNA expression levels from both tumor and normal tissues. Normalized quantification expression levels for these 50 participants were further examined for each investigated miRNA.

Pathway enrichment analysis
---------------------------

We attempted to determine the functions of the miRNA target genes by investigating the pathways with which the miRNA target genes were involved. Therefore, we first downloaded the target genes of differentially expressed miRNAs from TargetScan 6.0, and then mapped the target genes onto the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways based on the Enzyme Commission (EC) numbers by using the R package SubPathwayMiner v.3.1 ([@b27-or-31-03-1067]). Subsequently, the hypergeometric test was performed to identify significantly enriched pathways and calculate the false positive discovery rate in the FDR-corrected q-value.

Results
=======

miRNA profiling of radiation-treated prostate cancer cells
----------------------------------------------------------

To characterize the mechanism involved in the radiation response of prostate cancer, we used NGS to comprehensively analyze the distribution of miRNAs after radiation treatment in PC3 cells. As indicated in [Fig. 1A](#f1-or-31-03-1067){ref-type="fig"}, PC3 cells were exposed to various dosages of radiation (0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 Gy) and then subjected to a fresh culture medium for an additional 4 days. We found that the growth of the PC3 cells obviously decreased when exposed to 10 Gy of radiation. Therefore, we collected cell RNA at various times (0, 5, 15 and 40 h) following the 10-Gy radiation treatment. We confirmed the expression levels of Cox-2 and p21, which may be induced by radiation at 24 h according to previous studies ([@b16-or-31-03-1067],[@b28-or-31-03-1067]). The expression levels of Cox-2 and p21 may be upregulated by radiation treatment in PC3 cells ([Fig. 1B](#f1-or-31-03-1067){ref-type="fig"}). We then performed the comprehensive miRNA profile at various time-points in radiation-treated PC3 cells by using the Illumina HiSeq platform.

Analysis of miRNA sequence reads
--------------------------------

Once the samples were sequenced, we collected \>9 million clean reads in all libraries ([Table I](#tI-or-31-03-1067){ref-type="table"}). In addition to miRNA, we also determined which molecules were the remaining non-miRNA reads. By mapping the non-miRNA reads back to a different data set, we classified the reads into 11 categories. [Fig. 1C](#f1-or-31-03-1067){ref-type="fig"} demonstrates that miRNA accounted for 80% of all clean reads in the prostate cell libraries. Other categories accounted for relatively low proportions, which indicated the high performance of the sample preparation protocol. In addition, the proportions of the categories were considerably similar among libraries, indicating that radiation treatment did not alter the composition of RNA samples in the prostate cell libraries.

After mapping the clean reads to the genome, most of the miRNA reads tend to exist as isomiR. As demonstrated in [Fig. 2A](#f2-or-31-03-1067){ref-type="fig"}, hsa-miR-2110-5p had 5 isomers, whereas the opposite-arm miRNA-3p had 15 isomiRs, which demonstrated that abundant miRNAs tend to have more isomiRs. Our data revealed that the isomiR quantity was highly correlated with miRNA abundance (Pearson's correlation coefficient, 0.91). In addition, we observed that the modified nucleotides were preferentially located at the 3′ end of the sequence read (presented in lower case in [Fig. 2A](#f2-or-31-03-1067){ref-type="fig"}). The data indicated that one A nucleotide or one U nucleotide was frequently added at the end of the read. Notably, we found that the proportion of AA dinucleotides modified at the end of the read was gradually increased in a time-dependent manner after the PC3 cells were treated with radiation, which indicated that the 3′ end modification may be altered by radiation treatment in PC3 cells. Our previous studies indicated that the use of miR-5p and -3p may be altered in human cancer ([@b29-or-31-03-1067]--[@b31-or-31-03-1067]). In the present study, our data indicated that arm selection preference was consistent across nearly all libraries. Only a few cases were observed in which the use of -5p and -3p arm selection had different preferences at various time-points after radiation treatment ([Fig. 2C](#f2-or-31-03-1067){ref-type="fig"}). Further research is required to support these findings.

Radiation-response miRNAs in prostate cancer
--------------------------------------------

By summarizing the read count of all the isomiRs that belonged to the same mature miRNAs, we quantified the miRNA expression abundances, and presented the result in transcript per million (TPM). Twenty-two miRNAs were selected and are presented in [Table II](#tII-or-31-03-1067){ref-type="table"}, demonstrating that their expression levels were altered \>2-fold after being subjected to radiation exposure (expression of 6 miRNAs increased, and expression of 16 miRNAs decreased). To explore the putative role contributing to prostate cancer progression, we examined the effect of expression levels of radiation-associated miRNAs on prostate cancer from the available TCGA dataset by using an *in silico* analysis. We downloaded 100 miRNA expression profiles from 50 prostate cancer patients, including 50 cancer lesion and 50 corresponding normal tissues. As demonstrated in [Fig. 3A](#f3-or-31-03-1067){ref-type="fig"}, the expression levels of radiation-induced miRNAs, miR-25, miR-30a and miR-550a, were significantly upregulated in the prostate cancer cells compared with the corresponding normal tissue cells. Twelve radiation-suppressed miRNAs were identified, i.e. let-7d, miR-15a, miR-17, miR-30d, miR-92a, miR-197, miR-221, miR-320b, miR-342, miR-361, miR-501 and miR-671, and a significantly different expression between prostate cancer and the corresponding adjacent part was found, including 11 upregulated and 1 downregulated ([Fig. 3B](#f3-or-31-03-1067){ref-type="fig"}). Overall, the data indicated that most of the radiation-response miRNAs were identified as dysregulated in prostate cancer according to an *in silico* analysis (15/22; 1 downregulated, 14 upregulated and the rest demonstrated no change in expression in prostate cancer).

Pathway enrichment analysis of miRNAs
-------------------------------------

miRNAs can function as either oncogenes or tumor suppressors depending on their target genes. Therefore, identifying a target can facilitate elucidating the role of miRNAs in prostate cancer treatment radiation ([@b32-or-31-03-1067],[@b33-or-31-03-1067]). Typically, one miRNA tends to have hundreds of target genes and a group of miRNAs co-modulated as a biological function involved in the regulation of a signaling pathway. Therefore, we further explored the biological function of radiation-response miRNAs by conducting a pathway-enrichment analysis. The putative target genes of miRNAs were obtained from TargetScan 6.0; subsequently, these target genes of the individual miRNAs were mapped onto KEGG pathways. Our data indicated that the target genes of radiation-response miRNAs were frequently significantly enriched in several cancer- or radiation-related pathways, including the mitogen-activated protein kinase (MAPK), ErbB, p53, Wnt, transforming growth factor-β (TGF-β) and mTOR signaling pathways with an *FDR* \<0.05 ([Table III](#tIII-or-31-03-1067){ref-type="table"}). We also subjected the target genes of the 2-gene set, upregulated miRNA and downregulated miRNAs, to pathway-enrichment analysis. Similar results were observed; their targets were significantly enriched in the prostate cancer pathway ([Fig. 4](#f4-or-31-03-1067){ref-type="fig"}) and radiation-related pathways, including the MAPK, ErbB, Wnt and TGF-β signaling pathways ([Tables IV](#tIV-or-31-03-1067){ref-type="table"} and [V](#tV-or-31-03-1067){ref-type="table"}).

Discussion
==========

Our previous studies indicated that the distributions of 3′ end modifications and the arm selection preference of miRNAs were different between normal and tumor tissues ([@b29-or-31-03-1067]--[@b31-or-31-03-1067]). The -5p and -3p of miRNA play a distant role by suppressing the different target genes. It was previously reported that, in contrast to the oncogenic effect of miR-17 (-5p), miR-17^\*^(-3P) plays a tumor suppressive role in prostate cancer ([@b9-or-31-03-1067],[@b34-or-31-03-1067],[@b35-or-31-03-1067]). The miR-28-5p and miR-28-3p also play opposite roles in colon cancer cell proliferation and migration ([@b36-or-31-03-1067]). In the present study, our data showed that the -5p and -3p of particular miRNAs were differently regulated by radiation (shown in [Fig. 2C](#f2-or-31-03-1067){ref-type="fig"}). Several studies have demonstrated that miRNAs contain various ends, which were caused by either RNA editing or non-template nucleotide additions ([@b17-or-31-03-1067],[@b18-or-31-03-1067],[@b20-or-31-03-1067]). These miRNA isoforms (isomiRs) contribute to increased miRNA stability or strengthened miRNA-target gene interaction and are differentially expressed in different cellular conditions, including cancer ([@b16-or-31-03-1067],[@b37-or-31-03-1067],[@b38-or-31-03-1067]). Our data revealed that the proportion of AA dinucleotide modifications at the end of the read gradually increased in a time-dependent manner after the PC3 cells were treated with radiation, suggesting that radiation may influence the particular miRNA stability or efficiency of silencing targets by regulating the 3′ end modifications, which warrants further research.

miRNAs are known to function as gene silencers and are involved in modulating biological functions, including cell growth, apoptosis, the cell cycle and the metastasis of cancer ([@b39-or-31-03-1067]). Comprehensive miRNA profiling of prostate cancer has indicated that several miRNAs are differentially expressed between prostate cancer and the adjacent normal, which contributes to prostate cancer progression ([@b40-or-31-03-1067]--[@b42-or-31-03-1067]). In the present study, we analyzed miRNA expression from TCGA database and found that the expression levels of radiation-induced miRNAs were frequently dysregulated in prostate cancer ([Fig. 3](#f3-or-31-03-1067){ref-type="fig"}). Our results are consistent with those of previous studies and demonstrated that miR-25, miR-17, miR-30d and miR-92a are overexpressed, and miR-221 is downregulated in prostate cancer ([@b9-or-31-03-1067],[@b42-or-31-03-1067]--[@b44-or-31-03-1067]). However, the expression levels of let-7d and miR-15a decreased according to TCGA, which contradicted the results of previous studies ([@b45-or-31-03-1067]--[@b47-or-31-03-1067]). These dysfunctional miRNAs have potential to be used as biomarkers for prostate cancer prognosis or diagnosis. Therefore, understanding the function of miRNAs may provide practical benefits for clinical applications. Predicting the outcome of cancer treatment is the most promising application of miRNAs. Gonzales *et al* found miR-141 to be consistent with changes in other conventional biomarkers and to the clinical outcomes, suggesting that miR-141 can be used as a marker for monitoring therapeutic response in prostate cancer patients ([@b48-or-31-03-1067]). The prognostic value of miRNA expression profiling in prostate cancer has also been demonstrated by Hulf *et al*. They demonstrated that DNA methylation and histone H3K9-deacetylation of the miR-205 locus is associated with miRNA silencing and deregulation of MED1, which is predictive of a poor prognosis in localized prostate cancer ([@b49-or-31-03-1067]).

Ionizing radiation is one of the 3 primary modalities used in cancer therapy. Radiation induces considerable DNA damages, which, if not repaired, cause cancer cells to progress to apoptosis and cell cycle arrest. Some cancer cells are resistant to radiation treatment due to activation of complex signaling pathways that counteract these damages, including ErbB, nuclear factor κB (NFκB), MAPK, PI3K/AKT and transforming growth factor-β (TGF-β) signaling pathways ([@b50-or-31-03-1067]--[@b52-or-31-03-1067]). Several radiation-related miRNAs have been identified that contribute to the radiosensitivity of cancer cells by modulating the radiation-response signaling pathway ([@b51-or-31-03-1067],[@b52-or-31-03-1067]). Since miRNAs are generally slightly repressed by their target genes, the alteration of an individual miRNA is insufficient for accomplishing a biological function. Previous studies have introduced the concept of miRNA regulatory modules (MRMs), which potentially serve as a model for understanding the detailed influences of miRNAs in cellular biological functions ([@b53-or-31-03-1067]--[@b55-or-31-03-1067]). Therefore, in the present study, we were particularly interested in the consequences of changes in a group of radiation-induced miRNAs in prostate cancer. Our data indicated that targets of the co-expressed miRNAs were enriched in a radiation-related signaling pathway, suggesting that they co-modulated an abundance of target genes in the same pathway ([Table III](#tIII-or-31-03-1067){ref-type="table"}).

miRNAs regulate various factors in radiation-related biological pathways and may affect the radiosensitivity of tumor cells ([@b51-or-31-03-1067]). Radiation-response miRNAs have been identified in prostate cancer by using a microarray approach ([@b13-or-31-03-1067]--[@b15-or-31-03-1067]). By comparing these data, we identified known and unknown radiation-response miRNAs in prostate cancer by using an NGS approach. Li *et al* reported that the expression levels of miR-9, miR-22 and miR-30a decreased in radiation-treated PC3 cells ([@b14-or-31-03-1067]). Radiation reduced the expression level of an miR-17-92a cluster and the let-7 family in prostate cancer ([@b15-or-31-03-1067]). In the present study, we also identified radiation-response miRNAs that had been reported in other types of cancer but not in prostate cancer, such as miR-25, miR-15a, miR-30d, miR-125a, miR-221 and miR-342 ([@b21-or-31-03-1067],[@b56-or-31-03-1067]--[@b63-or-31-03-1067]). In addition, we identified a group of radiation-response miRNAs that have not been reported in any type of cancer. The pathway-enrichment analysis revealed that their targets are frequently enriched in the radiation-response signaling pathway.

In summary, in the present study, we thoroughly investigated radiation-response miRNAs, which may be involved in the radiosensitivity of prostate cancer, by modulating radiation-related signaling pathways using an NGS approach. These miRNA candidates may be effective targets for improving the efficacy of radiation treatment in future prostate cancer therapy. In addition, we observed that 3′ end modifications and the -5p/-3p arm selection of miRNAs were altered in prostate cancer after radiation treatment. These finding require further research.
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![Radiation treatment of human prostate cancer cells, PC3. (A) PC3 cells were treated with various radiation doses (0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 Gy) and were subsequently subjected to fresh culture medium. After culturing for an additional 4 days, the morphology was observed using light microscopy (x40 magnification). (B) The expression pattern of COX-2 and p21 in radiation-treated PC3 cells was examined using a real-time PCR method. S26 was used as an internal control. (C) The distribution of small RNA reads in 11 categories was classified.](OR-31-03-1067-g00){#f1-or-31-03-1067}

![The distribution of isomiRs and -5p/-3p arm selection in PC3 radiation treatment. (A) Mapping results of hsa-miR-2110. As shown in 5p:8--29, hsa-miR-2110 encodes mature miRNA at only its 5 p arm, and miRNA spans from nucleotide 8 to nucleotide 29 of the hairpin. The integer values on the left denote the read count of each isomiR. The comma-separated values denote the position shift in the isomiR relative to the miRBase annotated positions (8 to 29). The nucleotides in lowercase type denote the sequence fragments originating from the 3′ modification event. (B) The proportion of 3′ modifications at end of reads at different time-points after PC3 radiation treatment as observed from NGS data. (C) Fold-change of the -5p/-3p arm of miRNA at different time points after PC3 radiation treatment as observed from NGS data. isomiRs, miRNA isoforms; miRNA, microRNA; NGS, next-generation sequencing.](OR-31-03-1067-g01){#f2-or-31-03-1067}

![(A) Expression levels of radiation-induced miRNAs in prostate cancer. (B) Expression levels of radiation-suppressed miRNAs in prostate cancer. Expression levels of miRNAs between tumor and corresponding normal tissues from 50 prostate cancer patients were analyzed using TCGA dataset. The expression levels of miRNAs were presented in transcript per million (TPM). The expression level between tumor and normal cells was evaluated by conducting paired t-tests (P\<0.05 was considered significant; NS, non-significant. ^\*^P\<0.05, ^\*\*^P\<0.01, ^\*\*\*^P\<0.001). TCGA, The Cancer Genome Atlas.](OR-31-03-1067-g02){#f3-or-31-03-1067}

![The enriched pathway of the target gene union of radiation-response miRNAs. (A) The target gene union of radiation-upregulated miRNAs enriched in the prostate cancer pathway (*FDR*=0.001). (B) The target gene union of radiation-downregulated miRNAs enriched in the prostate cancer pathway (*FDR*=3.6E-9). The target genes are labeled in red.](OR-31-03-1067-g03){#f4-or-31-03-1067}

###### 

Summary of sequence reads and the detected miRNAs.

  -----------------------------------------------------------------
  Library   Clean read (n)   miRNA read (%)   pre-miRNA\   miRNA\
                                              (n)          (n)
  --------- ---------------- ---------------- ------------ --------
  P_C       9,482,400        80.49            693          916

  P_5       9,748,570        79.75            687          915

  P_15      9,589,440        80.35            712          933

  P_40      10,589,934       80.86            739          964
  -----------------------------------------------------------------

P_C, P_5, P_15 and P_40 are prostate cancer cell lines with different radiation treatment. By mapping the clean sequence reads back to pre-miRNAs, we can quantify how many pre-miRNAs and mature miRNAs were detected.

###### 

miRNAs with altered expression in response to radiation in PC3 cells using next-generation sequencing.

                                                                0 h   5 h    15 h   40 h   Expression data for TCGA
  ------------------------------------------------------------- ----- ------ ------ ------ -------------------------------------------------------------
  Upregulation[a](#tfn2-or-31-03-1067){ref-type="table-fn"}                                
   hsa-miR-9-5p                                                 1     2.82   0.90   2.63   
   hsa-miR-22-3p                                                1     1.60   2.85   2.73   
   hsa-miR-25-3p                                                1     1.54   1.39   2.33   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-30a-5p                                               1     2.81   2.43   2.33   Upregulation[c](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-550a-3p                                              1     1.88   1.46   2.09   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-548h-5p                                              1     0.50   0.44   2.56   
  Downregulation[b](#tfn3-or-31-03-1067){ref-type="table-fn"}                              
   hsa-let-7c                                                   1     0.93   0.78   0.45   
   hsa-let-7d-5p                                                1     0.30   0.11   0.40   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-let-7e-5p                                                1     0.58   0.55   0.40   
   hsa-miR-15a-5p                                               1     0.78   0.67   0.45   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-17-3p                                                1     0.52   0.49   0.47   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-30d-3p                                               1     0.92   0.75   0.41   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-92a-5p                                               1     0.65   0.52   0.50   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-125a-3p                                              1     0.42   0.42   0.32   
   hsa-miR-197-3p                                               1     0.77   0.79   0.44   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-221-5p                                               1     0.59   0.31   0.44   Downregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-320b                                                 1     0.65   0.41   0.32   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-342-5p                                               1     0.59   0.63   0.47   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-361-3p                                               1     0.45   0.53   0.40   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-374a-5p                                              1     1.04   0.93   0.47   
   hsa-miR-501-3p                                               1     0.77   0.48   0.45   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}
   hsa-miR-671-3p                                               1     0.77   0.62   0.41   Upregulation[d](#tfn3-or-31-03-1067){ref-type="table-fn"}

Expression levels of miRNA were inducted \>2-fold change after PC3 radiation treatment with 10 Gy for 40 h.

Expression levels of miRNA were repressed \>2-fold change after PC3 radiation treatment with 10 Gy for 40 h.

The difference was indicated to be significant with p-value less than 0.01 or 0.001.

###### 

The enriched pathways of radiation-induced miRNA target genes.

  microRNA           Cancer-relative pathway (FDR\<0.05)
  ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulation       
   hsa-miR-9-5p      Focal adhesion, pathways in cancer, **[ErbB signaling pathway]{.ul}**, **[MAPK signaling pathway]{.ul}**, prostate cancer
   hsa-miR-22-3p     Chronic myeloid leukemia, **[MAPK signaling pathway]{.ul}**, **[ErbB signaling pathway]{.ul}**, pathways in cancer, glioma, prostate cancer, **[phosphatidylinositol signaling system]{.ul}**, colorectal cancer
   hsa-miR-25-3p     N.D
   hsa-miR-30a-5p    N.D
   hsa-miR-550a-3p   N.D
   hsa-miR-548h-5p   N.D
  Downregulation     
   hsa-let-7c        **[MAPK signaling pathway]{.ul}**, pathways in cancer, **p53 signaling pathway**, melanoma, chronic myeloid leukemia, glioma, pancreatic cancer, focal adhesion, small cell lung cancer, bladder cancer, prostate cancer
   hsa-let-7d-5p     **[MAPK signaling pathway]{.ul}**, pathways in cancer, **p53 signaling pathway**, melanoma, chronic myeloid leukemia, glioma, pancreatic cancer, focal adhesion, small cell lung cancer, bladder cancer, **[prostate cancer]{.ul}**
   hsa-let-7e-5p     **[MAPK signaling pathway]{.ul}**, pathways in cancer, **p53 signaling pathway**, melanoma, chronic myeloid leukemia, glioma, pancreatic cancer, focal adhesion, small cell lung cancer, bladder cancer, prostate cancer
   hsa-miR-15a-5p    Pathways in cancer, regulation of actin cytoskeleton, renal cell carcinoma, **[MAPK signaling pathway]{.ul}**, focal adhesion, melanoma, **[prostate cancer]{.ul}**, **[Wnt signaling pathway]{.ul}**, **p53 signaling pathway**, **[mTOR signaling pathway]{.ul}**, non-small cell lung cancer, pancreatic cancer, cell cycle
   hsa-miR-17-3p     **[MAPK signaling pathway]{.ul}**, pathways in cancer, chronic myeloid leukemia, pancreatic cancer, melanoma, bladder cancer, **[TGF-β signaling pathway]{.ul}**, **[prostate cancer]{.ul}**, **[mTOR signaling pathway]{.ul}**, non-small cell lung cancer, renal cell carcinoma, **cell cycle**, **p53 signaling pathway**
   hsa-miR-30d-3p    N.D
   hsa-miR-92a-5p    N.D
   hsa-miR-125a-3p   **[MAPK signaling pathway]{.ul}**, adherens junction, pancreatic cancer, **[TGF-β signaling pathway]{.ul}**
   hsa-miR-197-3p    N.D
   hsa-miR-221-5p    **[Wnt signaling pathway]{.ul}**, **[ErbB signaling pathway]{.ul}** hsa-miR-320b Chronic myeloid leukemia, non-small cell lung cancer, glioma, pathways in cancer, focal adhesion, pancreatic cancer, melanoma, **[ErbB signaling pathway]{.ul}**, colorectal cancer, **[TGF-β signaling pathway]{.ul}**, prostate cancer, **[MAPK signaling pathway]{.ul}**, **[mTOR signaling pathway]{.ul}**
   hsa-miR-342-5p    N.D
   hsa-miR-361-3p    Pathways in cancer, **[mTOR signaling pathway]{.ul}**, melanogenesis, renal cell carcinoma, **[nucleotide excision repair]{.ul}**
   hsa-miR-374a-5p   Pathways in cancer, prostate cancer, **[TGF-β signaling pathway]{.ul}**, endometrial cancer, non-small cell lung cancer, basal cell carcinoma, **[MAPK signaling pathway]{.ul}**
   hsa-miR-501-3p    N.D
   hsa-miR-671-3p    N.D

###### 

The enriched pathways of radiation-upregulated miRNA target genes.

  Pathway Id   Pathway name                                             FDR
  ------------ -------------------------------------------------------- ----------
  Path:04360   Axon guidance                                            7.88E-08
  Path:04722   Neurotrophin signaling pathway                           1.11E-07
  Path:04010   **[MAPK signaling pathway]{.ul}**                        1.11E-07
  Path:05200   Pathways in cancer                                       3.25E-07
  Path:04012   **[ErbB signaling pathway]{.ul}**                        3.14E-06
  Path:04120   Ubiquitin mediated proteolysis                           8.82E-06
  Path:04144   Endocytosis                                              1.24E-05
  Path:04520   Adherens junction                                        5.86E-05
  Path:05412   Arrhythmogenic right ventricular cardiomyopathy (ARVC)   7.26E-05
  Path:04510   Focal adhesion                                           0.000105
  Path:04916   Melanogenesis                                            0.000245
  Path:05220   Chronic myeloid leukemia                                 0.000245
  Path:04810   Regulation of actin cytoskeleton                         0.000261
  Path:05214   Glioma                                                   0.000261
  Path:05414   Dilated cardiomyopathy                                   0.000268
  Path:04910   Insulin signaling pathway                                0.000282
  Path:04720   Long-term potentiation                                   0.000294
  Path:04070   **[Phosphatidylinositol signaling system]{.ul}**         0.000294
  Path:05410   Hypertrophic cardiomyopathy (HCM)                        0.000802
  Path:05100   Bacterial invasion of epithelial cells                   0.001018
  Path:05215   **[Prostate cancer]{.ul}**                               0.001096
  Path:04310   **[Wnt signaling pathway]{.ul}**                         0.001153
  Path:04914   Progesterone-mediated oocyte maturation                  0.002548
  Path:05211   Renal cell carcinoma                                     0.003135
  Path:04920   Adipocytokine signaling pathway                          0.003902
  Path:04350   **[TGF-β signaling pathway]{.ul}**                       0.003902
  Path:04666   Fc γ R-mediated phagocytosis                             0.004314
  Path:04141   Protein processing in endoplasmic reticulum              0.005738
  Path:05210   Colorectal cancer                                        0.005747
  Path:04130   SNARE interactions in vesicular transport                0.007624
  Path:05216   Thyroid cancer                                           0.008679
  Path:00562   Inositol phosphate metabolism                            0.008679
  Path:00532   Glycosaminoglycan biosynthesis-chondroitin sulfate       0.008679
  Path:05014   Amyotrophic lateral sclerosis (ALS)                      0.008679
  Path:05212   Pancreatic cancer                                        0.008679
  Path:04020   Calcium signaling pathway                                0.008679
  Path:05218   Melanoma                                                 0.010147
  Path:04930   Type II diabetes mellitus                                0.018227
  Path:04962   Vasopressin-regulated water reabsorption                 0.018227
  Path:04530   Tight junction                                           0.019289
  Path:04512   ECM-receptor interaction                                 0.019289
  Path:04912   GnRH signaling pathway                                   0.019289
  Path:05223   Non-small cell lung cancer                               0.023349
  Path:05222   Small cell lung cancer                                   0.032425
  Path:05213   Endometrial cancer                                       0.035464
  Path:04662   B cell receptor signaling pathway                        0.035464
  Path:05131   Shigellosis                                              0.035464
  Path:05221   Acute myeloid leukemia                                   0.03804
  Path:04540   Gap junction                                             0.041068
  Path:00250   Alanine, aspartate and glutamate metabolism              0.045237
  Path:04114   Oocyte meiosis                                           0.049286

###### 

The enriched pathways of radiation-downregulated miRNA target genes.

  Pathway Id   Pathway name                                             FDR
  ------------ -------------------------------------------------------- ----------
  Path:04010   **[MAPK signaling pathway]{.ul}**                        0
  Path:04360   Axon guidance                                            0
  Path:05200   **[Pathways in cancer]{.ul}**                            0
  Path:04722   Neurotrophin signaling pathway                           1.18E-12
  Path:04310   **[Wnt signaling pathway]{.ul}**                         1.50E-10
  Path:04510   Focal adhesion                                           4.27E-10
  Path:04144   Endocytosis                                              1.40E-09
  Path:04810   Regulation of actin cytoskeleton                         2.34E-09
  Path:05215   **[Prostate cancer]{.ul}**                               3.58E-09
  Path:05211   Renal cell carcinoma                                     3.58E-09
  Path:04720   Long-term potentiation                                   1.14E-08
  Path:05220   Chronic myeloid leukemia                                 3.41E-08
  Path:04120   Ubiquitin mediated proteolysis                           7.40E-08
  Path:04020   **[Calcium signaling pathway]{.ul}**                     1.10E-07
  Path:05212   Pancreatic cancer                                        1.57E-07
  Path:05214   Glioma                                                   1.59E-07
  Path:05218   Melanoma                                                 2.36E-07
  Path:05223   Non-small cell lung cancer                               3.64E-07
  Path:04916   Melanogenesis                                            4.67E-07
  Path:04520   Adherens junction                                        4.67E-07
  Path:04910   Insulin signaling pathway                                6.79E-07
  Path:04350   **[TGF-β signaling pathway]{.ul}**                       7.72E-07
  Path:05210   Colorectal cancer                                        2.50E-06
  Path:04012   **[ErbB signaling pathway]{.ul}**                        3.89E-06
  Path:05222   Small cell lung cancer                                   3.20E-05
  Path:04730   Long-term depression                                     5.13E-05
  Path:05221   Acute myeloid leukemia                                   7.50E-05
  Path:04150   **[mTOR signaling pathway]{.ul}**                        8.68E-05
  Path:05213   Endometrial cancer                                       8.68E-05
  Path:05217   Basal cell carcinoma                                     9.44E-05
  Path:04710   Circadian rhythm-mammal                                  9.64E-05
  Path:04070   Phosphatidylinositol signaling system                    9.64E-05
  Path:04540   Gap junction                                             9.83E-05
  Path:04115   **[p53 signaling pathway]{.ul}**                         0.000113
  Path:04141   Protein processing in endoplasmic reticulum              0.000137
  Path:04114   Oocyte meiosis                                           0.000196
  Path:05014   Amyotrophic lateral sclerosis (ALS)                      0.000353
  Path:04970   Salivary secretion                                       0.000414
  Path:04660   T cell receptor signaling pathway                        0.000449
  Path:04666   Fc γ R-mediated phagocytosis                             0.000526
  Path:04512   ECM-receptor interaction                                 0.000526
  Path:05142   Chagas disease                                           0.000563
  Path:04062   Chemokine signaling pathway                              0.000812
  Path:04210   **[Apoptosis]{.ul}**                                     0.000844
  Path:04914   Progesterone-mediated oocyte maturation                  0.001465
  Path:04110   **[Cell cycle]{.ul}**                                    0.001527
  Path:04662   B cell receptor signaling pathway                        0.00169
  Path:04530   Tight junction                                           0.001692
  Path:04930   Type II diabetes mellitus                                0.002128
  Path:05412   Arrhythmogenic right ventricular cardiomyopathy (ARVC)   0.002128
  Path:04920   Adipocytokine signaling pathway                          0.002184
  Path:04664   Fc ɛ RI signaling pathway                                0.002621
  Path:04960   Aldosterone-regulated sodium reabsorption                0.002802
  Path:04912   GnRH signaling pathway                                   0.002955
  Path:04320   Dorso-ventral axis formation                             0.00373
  Path:05219   Bladder cancer                                           0.00373
  Path:04340   Hedgehog signaling pathway                               0.005218
  Path:04971   Gastric acid secretion                                   0.005633
  Path:04130   SNARE interactions in vesicular transport                0.006926
  Path:00532   Glycosaminoglycan biosynthesis-chondroitin sulfate       0.006926
  Path:05131   Shigellosis                                              0.008185
  Path:05160   Hepatitis C                                              0.008185
  Path:04630   Jak-STAT signaling pathway                               0.008368
  Path:05410   Hypertrophic cardiomyopathy (HCM)                        0.009939
  Path:05414   Dilated cardiomyopathy                                   0.010733
  Path:00534   Glycosaminoglycan biosynthesis-heparan sulfate           0.011359
  Path:04670   Leukocyte transendothelial migration                     0.011852
  Path:04370   VEGF signaling pathway                                   0.013265
  Path:00562   Inositol phosphate metabolism                            0.013625
  Path:04270   Vascular smooth muscle contraction                       0.014557
  Path:00512   O-Glycan biosynthesis                                    0.016472
  Path:04330   Notch signaling pathway                                  0.026769
  Path:04142   Lysosome                                                 0.038882
  Path:00533   Glycosaminoglycan biosynthesis-keratan sulfate           0.038882
  Path:05145   Toxoplasmosis                                            0.048785
